Company Overview and News
Emirates is banking on its new Bali route being popular with surfers by carrying boards for free on a route that is shaping up as a hotly contested one as Air New Zealand faces competition on direct services for the first time.
FGETF ANZLY AIR FGHRY ANZFF ANZFY AIZ
Just over 5 per cent of passengers fly business class or better but they provide nearly a third of annual global revenue for airlines which totals $1.1 trillion.
FGETF C6L ANZLY AIR FGHRY ANZFF SINGY ANZFY AIZ SINGF
Good morning and welcome to the Sabre First Quarter 2018 Earnings Conference Call. Please note that today's call is being recorded and is also being broadcast live over the Internet on the Sabre corporate website. This broadcast is the property of Sabre. Any redistribution, retransmission or rebroadcast of this call in any form without the express written consent of the company is strictly prohibited.
FGETF 0753 VA AICAF AFRAF ACDVF AIRC AIRYY FGHRY SABR AFLYY AC
Airfares for business travellers crept up steadily during the past year and are forecast to climb again this year, shows a report done for the travel industry.
C6L AIR CHEAF SINGY ANZFY CEA AIZ 0670 FGETF ANZLY FGHRY ANZFF SINGF
Branching off from the topic of relative density of academics (C8), one of the pet peeves of Tim Ingall from Scottsdale, Arizona, possessor of a fine set of educational post-nominals of his own, is "when someone with academic qualifications is interviewed and we are informed that the person is a Professor at Whatsamatter University (one for the Rocky and Bullwinkle fans), which provides absolutely no information regarding whether the professor is qualified to comment on the matter at hand.
Flight Centre has lost its long-running and expensive legal battle with competition watchdog, the ACCC, after being forced to pay $12.5 million in penalties relating to attempts to fix international flight prices.
21h - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
as of ET